STTK
NASDAQShattuck Labs Inc.
Price$5.44+0.02 (+0.37%)
01:30 PM07:45 PM
News · 26 weeks50+50%
2026-04-192026-10-11
Mix1190d
- Other3(27%)
- Analyst3(27%)
- SEC Filings3(27%)
- Offering1(9%)
- Leadership1(9%)
Latest news
25 items- PRShattuck Labs Announces Two Poster Presentations at UEG Week 2026AUSTIN, Texas and DURHAM, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced two upcoming poster presentations at United European Gastroenterology (UEG) Week 2026, taking place October 17–20, 2026, in Barcelona, Spain. Presentation Details Format: Moderated poster presentationTitle: Development and Characterization of SL-846: A Half-Life Extended, Dual-Receptor (DR3 x IL23RA) Targeting Bispecific Antibody
- ANALYSTUBS initiated coverage on Shattuck Labs with a new price targetUBS initiated coverage of Shattuck Labs with a rating of Buy and set a new price target of $17.00
- PRShattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development– RECEPTIVE-HS1 Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa (HS) expected to initiate in 2026; data from the 16-week treatment period expected in the first half of 2028 – – HS is the second Phase 2 indication for SL-325 and expands development beyond IBD – – Announces appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development; Dr. Ravichandran to lead the HS clinical development program – – Cash runway guidance remains unchanged, with existing cash expected to fund operations into 2029 – AUSTIN, TX and DURHAM, NC, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ:
- PRShattuck Labs Announces Participation in Upcoming September Investor ConferencesAUSTIN, Texas and DURHAM, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences: Conference Details Wells Fargo 21st Annual Healthcare Conference Format: Fireside chat and one-on-one meetingsPresenter: Taylor Schreiber, M.D., Ph.D., Chief Executive OfficerAdditional Management Participant: Andrew Neill, M
- ANALYSTRaymond James initiated coverage on Shattuck Labs with a new price targetRaymond James initiated coverage of Shattuck Labs with a rating of Strong Buy and set a new price target of $18.00
- SECSEC Form S-8 filed by Shattuck Labs Inc.S-8 - Shattuck Labs, Inc. (0001680367) (Filer)
- SECShattuck Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Shattuck Labs, Inc. (0001680367) (Filer)
- SECSEC Form 10-Q filed by Shattuck Labs Inc.10-Q - Shattuck Labs, Inc. (0001680367) (Filer)
- PRShattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights– Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling prolonged dosing intervals – – RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in patients with Crohn’s disease expected to initiate in the third quarter of 2026 – – Announced lead DR3 x IL-23 receptor blocking, half-life extended bispecific antibody product candidate, SL-846, with initial Phase 1 clinical data expected in 2027 – –Strengthened balance sheet with approximately $208.3 million in cash and cash equivalents and short-term investments as of June 30, 2026, expected to fund opera
- ANALYSTLeerink Partners initiated coverage on Shattuck Labs with a new price targetLeerink Partners initiated coverage of Shattuck Labs with a rating of Outperform and set a new price target of $16.00
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Shattuck Labs Inc.SCHEDULE 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)
- INSIDERChief Technical Officer Shukla Abhinav A. exercised 12,563 shares at a strike of $3.57 and sold $2,874 worth of shares (410 units at $7.01) as part of a pre-agreed trading plan, increasing direct ownership by 14% to 98,533 units (SEC Form 4) to satisfy withholding obligation4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERChief Technical Officer Shukla Abhinav A. exercised 23,465 shares at a strike of $3.57 and sold $166,131 worth of shares (23,465 units at $7.08) as part of a pre-agreed trading plan (SEC Form 4) (for tax liability)4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERChief Medical Officer Pandite Arundathy N. sold $210,300 worth of shares (30,000 units at $7.01) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 136,219 units (SEC Form 4)4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERSEC Form 4 filed by Director Ashiya Mona4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERSEC Form 4 filed by Director Orbimed Advisors Llc4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Shattuck Labs Inc.SCHEDULE 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Shattuck Labs Inc.SCHEDULE 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)
- INSIDERDirector Siegall Clay B bought $250,000 worth of shares (62,500 units at $4.00), increasing direct ownership by 24% to 318,608 units (SEC Form 4)4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- SECSEC Form 8-K filed by Shattuck Labs Inc.8-K - Shattuck Labs, Inc. (0001680367) (Filer)
- SECSEC Form 424B5 filed by Shattuck Labs Inc.424B5 - Shattuck Labs, Inc. (0001680367) (Filer)
- PRShattuck Labs, Inc. Announces Pricing of $75 Million Public OfferingAUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price per share of $4.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,870,624 shares of its common stock at a public offering price of $3.9999 per pre-funded war
- INSIDERSEC Form 4 filed by Director Orbimed Advisors Llc4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERSEC Form 4 filed by Director Ashiya Mona4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- SECSEC Form 424B5 filed by Shattuck Labs Inc.424B5 - Shattuck Labs, Inc. (0001680367) (Filer)
STTK FAQ
7 questionsWhat does Shattuck Labs Inc. do?
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.Where does STTK stock trade?
Shattuck Labs Inc. (STTK) is listed on NASDAQ.What sector and industry is STTK in?
Shattuck Labs Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Shattuck Labs Inc. go public?
Shattuck Labs Inc. (STTK) completed its IPO in 2020.What are analysts saying about STTK?
Shattuck Labs Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy with a $1700.00 price target on 2026-10-12.What companies are similar to STTK?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare STTK side-by-side with any of them on Quantisnow.How can I track STTK on Quantisnow?
Quantisnow aggregates Shattuck Labs Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STTK to receive live email and push alerts on every new disclosure.